Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Steffen PfeufferLeoni RolfesJens IngwersenRefik PulKonstanze KleinschnitzMelanie KorsenSaskia J RaeuberTobias RuckSimon SchieferdeckerAlice Grizzel WillisonOrhan AktasChristoph KleinschnitzHans-Peter HartungLudwig KapposSven G MeuthPublished in: Neurology(R) neuroimmunology & neuroinflammation (2023)
This study provides Class IV evidence that for patients with RMS, previous treatment with FTY compared with previous treatment with other immunomodulating therapies decreases the effectiveness of ocrelizumab.